Proven pulmonary aspergillosis in a COVID-19 patient: A case report.

Q3 Medicine

Current Medical Mycology Pub Date : 2021-06-01 DOI:10.18502/cmm.7.2.7031

Sadegh Khodavaisy, Nasim Khajavirad, Seyed Jamal Hashemi, Alireza Izadi, Seyed Ali Dehghan Manshadi, Alireza Abdollahi, Amir Aliramezani, Elahe Sasani, Mahsa Abdorahimi, Reyhaneh Sadat Kiyaeie, Zohre Khosravany, Muhammad Ibrahim Getso, Mohammadreza Salehi

{"title":"Proven pulmonary aspergillosis in a COVID-19 patient: A case report.","authors":"Sadegh Khodavaisy, Nasim Khajavirad, Seyed Jamal Hashemi, Alireza Izadi, Seyed Ali Dehghan Manshadi, Alireza Abdollahi, Amir Aliramezani, Elahe Sasani, Mahsa Abdorahimi, Reyhaneh Sadat Kiyaeie, Zohre Khosravany, Muhammad Ibrahim Getso, Mohammadreza Salehi","doi":"10.18502/cmm.7.2.7031","DOIUrl":null,"url":null,"abstract":"Background and purpose: Coronavirus disease 2019 (COVID-19) has become a significant clinical challenge in healthcare settings all over the world. Critically ill COVID-19 patients with acute respiratory distress syndrome may be at increased risk of co-infection with pulmonary aspergillosis. This study aimed to describe a clinical case of proven pulmonary aspergillosis caused by Aspergillus tubingensis in a 59-year-old man with a history of hospitalization due to COVID-19 infection.Case report: The Covid-19 infection was confirmed by positive nasopharyngeal polymerase chain reaction. He had a cavitary lesion measured 20 mm in diameter with intracavitary soft tissue density in the left lung in the first chest computerized tomography scan. After 25 days, he showed two cavitary lesions in both lungs which raised suspicion of fungal infection; hence, the patient underwent a trans-thoracic biopsy of the cavitary lesion. The direct examination and culture of the biopsy material revealed Aspergillus species. To confirm the Aspergillus species identification, the beta-tubulin region was sequenced. The patient was treated with oral voriconazole.Conclusion: This report underlined the importance of early diagnosis and management of invasive fungal infections in severe COVID-19 patients.","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"7 2","pages":"39-42"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740855/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Mycology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/cmm.7.2.7031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Background and purpose: Coronavirus disease 2019 (COVID-19) has become a significant clinical challenge in healthcare settings all over the world. Critically ill COVID-19 patients with acute respiratory distress syndrome may be at increased risk of co-infection with pulmonary aspergillosis. This study aimed to describe a clinical case of proven pulmonary aspergillosis caused by Aspergillus tubingensis in a 59-year-old man with a history of hospitalization due to COVID-19 infection.

Case report: The Covid-19 infection was confirmed by positive nasopharyngeal polymerase chain reaction. He had a cavitary lesion measured 20 mm in diameter with intracavitary soft tissue density in the left lung in the first chest computerized tomography scan. After 25 days, he showed two cavitary lesions in both lungs which raised suspicion of fungal infection; hence, the patient underwent a trans-thoracic biopsy of the cavitary lesion. The direct examination and culture of the biopsy material revealed Aspergillus species. To confirm the Aspergillus species identification, the beta-tubulin region was sequenced. The patient was treated with oral voriconazole.

Conclusion: This report underlined the importance of early diagnosis and management of invasive fungal infections in severe COVID-19 patients.

查看原文本刊更多论文

COVID-19患者肺部曲霉病1例报告

背景与目的:2019冠状病毒病(COVID-19)已成为世界各地卫生保健机构面临的重大临床挑战。COVID-19重症急性呼吸窘迫综合征患者合并肺曲霉病的风险可能增加。本研究旨在描述1例经证实由塔宾曲霉引起的肺部曲霉病的临床病例，该患者为59岁男性，因COVID-19感染而住院。病例报告:经鼻咽聚合酶链反应阳性确诊为新冠肺炎感染。在第一次胸部计算机断层扫描中，他有一个直径为20mm的腔内病变，左肺腔内软组织密度。25天后，他的双肺出现两个空洞病变，怀疑是真菌感染;因此，患者接受了经胸腔病变活检。活检材料的直接检查和培养显示曲霉属。为了确认曲霉的种类鉴定，对β -微管蛋白区域进行了测序。患者口服伏立康唑治疗。结论:本报告强调了COVID-19重症患者侵袭性真菌感染的早期诊断和治疗的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Medical Mycology Medicine-Infectious Diseases

CiteScore

2.10

自引率

0.00%

发文量

审稿时长

4 weeks